Cohort study on the treatment with dapsone 5% gel of mild to moderate inflammatory acne of the face in women

SKINmed

Volumn 12, Issue 1, 2014, Pages 15-21

  Lynde, Charles W ^a,b   Andriessen, Anneke ^c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b Lynde Centre for Dermatology   (Canada)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DAPSONE; DERMATOLOGICAL AGENT;

ACNE VULGARIS; ADOLESCENT; ADULT; AGED; ARTICLE; COHORT ANALYSIS; FACE; FEMALE; FOLLOW UP; GEL; HUMAN; INFLAMMATION; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ACNE VULGARIS; ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; COHORT STUDIES; DAPSONE; DERMATOLOGIC AGENTS; FACE; FEMALE; FOLLOW-UP STUDIES; GELS; HUMANS; INFLAMMATION; MIDDLE AGED; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899668196     PISSN: 15409740     EISSN: 17517125     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Perkins AC, Maglione J, Hillebrand GG, Miyamoto K, Kimball AB. Acne vulgaris in women: prevalence across the life span. J Womens Health (Larchmt). 2012;21:223–230.
2. Collier CN, Harper JC, Cantrell WC, et al. The prevalence of acne in adults 20 years and older. J Am Acad Dermatol. 2008;58:56–59.
3. Draelos ZD, Carter E, Maloney JM, et al. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol. 2007;56:439 e431–439 e410.
4. Thiboutot DM, Willmer J, Sharata H, Halder R, Garrett S. Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris. Clin Pharmacokinet. 2007;46:697–712.
5. Tanghetti E, Dhawan S, Green L, et al. Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris. J Drugs Dermatol. 2011;10:783–792.
6. Fleischer AB Jr., Shalita A, Eichenfield LF, et al. Dapsone gel combination treatment study group. Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12-week, randomized, double-blind study. J Drugs Dermatol. 2010;9:33–40.
7. Lucky AW, Malony JM, Roberts J, et al. Dapsone gel 5% for the treatment of acne vulgaris: safety and efficacy of long term (1 year) treatment. J Drugs Dermatol. 2007;6:981–987.
8. Piette WW, Taylor S, Pariser D, et al. Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris. Arch Dermatol. 2008;144:1564–1570.
9. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003;49:S200–S210.
10. Klassen AF, Newton JN, Mallon E. Measuring quality of life in people referred for specialist care of acne: comparing generic and disease-specific measures. J Am Acad Dermatol. 2000;43:229–233.
11. Lee IA, Maibach HI. Pharmionics in dermatology: a review of topical medication adherence. Am J ClinDermatol. 2006;7:231–236.
12. Tan JK, Balagurusamy M, Fung K, et al. Effect of quality of life impact and clinical severity on adherence to topical acne treatment. J Cutan Med Surg. 2009;13:204–208.